Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2

NCT01836575 is registered in ClinicalTrials.gov with Instituto Nacional de Cancer, Brazil as lead sponsor.

NCT NCT01836575
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01836575 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Trial of Single-Agent Pemetrexed (Alimta®) Versus the Combination of Carboplatin and Pemetrexed in Patients With Advanced Non-small-cell Lung Cancer and Performance Status of 2
Lead sponsor
Instituto Nacional de Cancer, Brazil
Phase
Phase 3
Overall status
Completed
Start date
April 30, 2008
Completion date
December 31, 2012
Enrollment
228 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

non small cell lung carcinoma